Fluidigm Corporation
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consum… Read more
Market Cap & Net Worth: Fluidigm Corporation (FLB)
Fluidigm Corporation (F:FLB) has a market capitalization of $323.69 Million (€315.34 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #22842 globally and #2486 in its home market, demonstrating a -2.96% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Fluidigm Corporation's stock price €0.82 by its total outstanding shares 384565414 (384.57 Million).
Fluidigm Corporation Market Cap History: 2015 to 2026
Fluidigm Corporation's market capitalization history from 2015 to 2026. Data shows change from $3.85 Billion to $323.69 Million (-19.55% CAGR).
Fluidigm Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Fluidigm Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.89x
Fluidigm Corporation's market cap is 3.89 times its annual revenue
0.72x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.85 Billion | $114.71 Million | -$53.31 Million | 33.53x | N/A |
| 2016 | $2.67 Billion | $104.45 Million | -$75.98 Million | 25.60x | N/A |
| 2017 | $2.00 Billion | $101.94 Million | -$60.53 Million | 19.62x | N/A |
| 2018 | $2.90 Billion | $112.96 Million | -$59.01 Million | 25.68x | N/A |
| 2019 | $1.17 Billion | $117.24 Million | -$64.79 Million | 9.97x | N/A |
| 2020 | $1.90 Billion | $138.14 Million | -$53.02 Million | 13.77x | N/A |
| 2021 | $1.28 Billion | $130.58 Million | -$59.24 Million | 9.79x | N/A |
| 2022 | $442.71 Million | $97.95 Million | -$190.10 Million | 4.52x | N/A |
| 2023 | $821.07 Million | $106.34 Million | -$74.66 Million | 7.72x | N/A |
| 2024 | $678.96 Million | $174.43 Million | -$138.88 Million | 3.89x | N/A |
Competitor Companies of FLB by Market Capitalization
Companies near Fluidigm Corporation in the global market cap rankings as of March 19, 2026.
Key companies related to Fluidigm Corporation by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
Fluidigm Corporation Historical Marketcap From 2015 to 2026
Between 2015 and today, Fluidigm Corporation's market cap moved from $3.85 Billion to $ 323.69 Million, with a yearly change of -19.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €323.69 Million | -22.64% |
| 2025 | €418.43 Million | -38.37% |
| 2024 | €678.96 Million | -17.31% |
| 2023 | €821.07 Million | +85.47% |
| 2022 | €442.71 Million | -65.38% |
| 2021 | €1.28 Billion | -32.77% |
| 2020 | €1.90 Billion | +62.77% |
| 2019 | €1.17 Billion | -59.73% |
| 2018 | €2.90 Billion | +45.08% |
| 2017 | €2.00 Billion | -25.21% |
| 2016 | €2.67 Billion | -30.49% |
| 2015 | €3.85 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Fluidigm Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $323.69 Million USD |
| MoneyControl | $323.69 Million USD |
| MarketWatch | $323.69 Million USD |
| marketcap.company | $323.69 Million USD |
| Reuters | $323.69 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.